Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 205 IDR -2.03% Market Closed
Market Cap: 56.4T IDR
Section:
 

Relative Value

The Relative Value of one KLBF stock under the Base Case scenario is hidden IDR. Compared to the current market price of 1 205 IDR, Kalbe Farma Tbk PT is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KLBF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
90
vs Industry
57
Median 3Y
2.3
Median 5Y
2.6
Industry
2.7
Forward
1.5
More Details
15.6
P/E
P/E
Price to Earnings
15.6
vs History
90
vs Industry
28
Median 3Y
24
Median 5Y
23.5
Industry
21.4
Forward
15
More Details
15.9
P/OCF
P/OCF
Price to OCF
15.9
vs History
74
vs Industry
36
Median 3Y
17.3
Median 5Y
17.9
Industry
16.8
More Details
23.4
P/FCFE
P/FCFE
Price to FCFE
23.4
vs History
77
vs Industry
24
Median 3Y
28.7
Median 5Y
32.4
Industry
23.1
More Details
2.4
P/B
P/B
Price to Book Value
2.4
vs History
90
vs Industry
31
Median 3Y
3.2
Median 5Y
3.6
Industry
2.3
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
90
vs Industry
60
Median 3Y
2.1
Median 5Y
2.5
Industry
2.9
Forward
1.4
More Details
3.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.7
vs History
90
vs Industry
48
Median 3Y
5.7
Median 5Y
6
Industry
5.5
More Details
11.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.7
vs History
90
vs Industry
28
Median 3Y
17.4
Median 5Y
17.2
Industry
13.3
Forward
9.5
More Details
11.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.7
vs History
90
vs Industry
32
Median 3Y
17.4
Median 5Y
17.2
Industry
16.5
Forward
11.1
More Details
14.8
EV/OCF
EV/OCF
Enterprise Value to OCF
14.8
vs History
74
vs Industry
38
Median 3Y
16.4
Median 5Y
16.6
Industry
16
More Details
19.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19.5
vs History
82
vs Industry
27
Median 3Y
22.9
Median 5Y
24.7
Industry
18.9
More Details
2.1
EV/IC
EV/IC
Enterprise Value to IC
2.1
vs History
88
vs Industry
33
Median 3Y
3
Median 5Y
3.4
Industry
2
More Details

Multiples Across Competitors

KLBF Competitors Multiples
Kalbe Farma Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Kalbe Farma Tbk PT
IDX:KLBF
54.6T IDR 1.6 15.6 11.7 11.7
US
Eli Lilly and Co
NYSE:LLY
982.2B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
526.1B USD 5.7 20.9 17.1 22.2
CH
Roche Holding AG
SIX:ROG
277.8B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP 5 31 108.8 159.2
CH
Novartis AG
SIX:NOVN
221.8B CHF 4.9 19.2 12.1 15.7
US
Merck & Co Inc
NYSE:MRK
270.7B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.5 16.6 11.6 13.4
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average P/E: 23.9
15.6
10%
1.6
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
31
37%
0.8
CH
Novartis AG
SIX:NOVN
19.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.6
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBITDA: 401.1
11.7
16%
0.7
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.6
1%
11.6
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Kalbe Farma Tbk PT
IDX:KLBF
Average EV/EBIT: 1 713.5
11.7
10%
1.2
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.2
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.7
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5

See Also

Summary
KLBF intrinsic value, competitors valuation, and company profile.
DCF Valuation
KLBF stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KLBF stock valuation using valuation multiples.
Wall Street Estimates
KLBF price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KLBF stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.